Breathe (Sheffield, England) · 2019
Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Turner Steve W, Chang Anne B, Yang Ian A
Аннотация
UNLABELLED: Exhaled nitric oxide fraction (F ENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. F ENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect F ENO, especially atopy, which is associated with elevated F ENO. One guideline recommends that F ENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged >5 years. The role of F ENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, F ENO is not recommended for diagnosis or monitoring of COPD. Although F ENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of F ENO as an objective measurement in asthma and COPD can be realised.
KEY POINTS: For individuals aged ≥12 years, F ENO is not recommended by all guidelines as a test to diagnose asthma (recommended only by the UK National Institute for Health and Care Excellence guideline for asthma symptoms, which are likely to respond to corticosteroid treatment).F ENO may be used in conjunction with other investigations to diagnose asthma in 5-16-year-olds where there is diagnostic uncertainty, but further evidence is required.F ENO is not recommended as a routine test to monitor all patients with asthma or to titrate asthma treatment.F ENO is not recommended for routine clinical testing in adults with COPD.F ENO may be useful to identify patients with COPD who could benefit from the use of inhaled corticosteroids (asthma-COPD overlap).
EDUCATIONAL AIMS: To understand what factors other than asthma and COPD affect F ENOTo understand the current controversies in the application of F ENO to diagnosis and management of asthma in childrenTo understand the current controversies in the application of F ENO to diagnosis and management of asthma and COPD in adults.
KEY POINTS: For individuals aged ≥12 years, F ENO is not recommended by all guidelines as a test to diagnose asthma (recommended only by the UK National Institute for Health and Care Excellence guideline for asthma symptoms, which are likely to respond to corticosteroid treatment).F ENO may be used in conjunction with other investigations to diagnose asthma in 5-16-year-olds where there is diagnostic uncertainty, but further evidence is required.F ENO is not recommended as a routine test to monitor all patients with asthma or to titrate asthma treatment.F ENO is not recommended for routine clinical testing in adults with COPD.F ENO may be useful to identify patients with COPD who could benefit from the use of inhaled corticosteroids (asthma-COPD overlap).
EDUCATIONAL AIMS: To understand what factors other than asthma and COPD affect F ENOTo understand the current controversies in the application of F ENO to diagnosis and management of asthma in childrenTo understand the current controversies in the application of F ENO to diagnosis and management of asthma and COPD in adults.